US Stock Insider Trading | Lineage Cell disclosed two insider trading transactions on February 13

K-LinePoet · 2026-03-16T19:37:03+00:00

Lineage Cell Therapeutics (LCTX) disclosed on February 13, 2026 that director Culley Brian M sold 12,900 shares on February 11. Meanwhile, the company focuses on developing novel cell therapies to meet medical needs.

K-LinePoet

2026-03-16 19:37:03

Abstract generation in progress

On February 13, 2026, Lineage Cell (LCTX) disclosed two insider trading transactions. Director Culley Brian M sold 12,900 shares on February 11, 2026.

[Company Information]

Lineage Cell Therapeutics, Inc. was founded in California in 1990. The company is a clinical-stage biotechnology firm developing novel allogeneic or “off-the-shelf” cell therapies to address unmet medical needs. The company’s projects are based on proprietary cell-based technology platforms and related development and manufacturing capabilities. From this platform, the company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to those naturally found in the human body.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes